Evermore Global Advisors LLC Buys 877,255 Shares of Enzo Biochem, Inc. (ENZ)

Evermore Global Advisors LLC raised its holdings in Enzo Biochem, Inc. (NYSE:ENZ) by 23.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,562,775 shares of the medical research company’s stock after buying an additional 877,255 shares during the period. Enzo Biochem accounts for about 15.0% of Evermore Global Advisors LLC’s portfolio, making the stock its 2nd largest holding. Evermore Global Advisors LLC owned about 9.72% of Enzo Biochem worth $37,187,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. CAPROCK Group Inc. acquired a new stake in Enzo Biochem in the 3rd quarter valued at $118,000. Legal & General Group Plc grew its position in shares of Enzo Biochem by 10.6% in the 2nd quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after acquiring an additional 1,022 shares during the period. Magnetar Financial LLC bought a new position in shares of Enzo Biochem in the 3rd quarter valued at about $121,000. Cubist Systematic Strategies LLC bought a new position in shares of Enzo Biochem in the 2nd quarter valued at about $124,000. Finally, LMR Partners LLP bought a new position in shares of Enzo Biochem in the 3rd quarter valued at about $149,000. Hedge funds and other institutional investors own 65.38% of the company’s stock.

Enzo Biochem, Inc. (NYSE ENZ) opened at $6.90 on Thursday. Enzo Biochem, Inc. has a 12-month low of $6.38 and a 12-month high of $12.04. The company has a market cap of $323.79, a PE ratio of -172.50 and a beta of 0.70.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Thursday, December 7th. The medical research company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Enzo Biochem had a negative net margin of 1.53% and a negative return on equity of 1.89%. The company had revenue of $27.68 million during the quarter, compared to the consensus estimate of $27.51 million.

In other news, CFO Barry W. Weiner sold 11,000 shares of Enzo Biochem stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the transaction, the chief financial officer now owns 1,313,111 shares of the company’s stock, valued at approximately $10,176,610.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Elazar Rabbani sold 14,000 shares of Enzo Biochem stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total transaction of $108,500.00. Following the sale, the chief executive officer now directly owns 1,867,202 shares of the company’s stock, valued at approximately $14,470,815.50. The disclosure for this sale can be found here. Company insiders own 8.90% of the company’s stock.

WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/15/evermore-global-advisors-llc-grows-position-in-enzo-biochem-inc-enz.html.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply